Apraglutide

At a glance

Overview

Apraglutide is designed to improve intestinal adaptation and absorption in people who need intravenous fluid or nutrition because too little functioning bowel remains. Its long action supports investigation as a weekly treatment. The STARS trial evaluated patients with different intestinal anatomies, including a stoma or colon in continuity. Not every secondary endpoint was positive, and treatment response cannot be inferred from the overall trial average alone. In 2025 the FDA requested another confirmatory phase 3 study, and the sponsor’s 2026 plans include STARS-2. This distinguishes demonstrated trial activity from a completed approval process.

Supporting sources [1] [2] [3] [4]

How it works

Apraglutide activates the GLP-2 receptor, supporting intestinal mucosal adaptation and absorptive function. Longer exposure is intended to reduce administration frequency relative to shorter-acting GLP-2 therapy. Increased uptake of fluid and nutrients may reduce parenteral-support requirements, but must be balanced against changing hydration needs. A trophic intestinal mechanism also creates questions about obstruction, abnormal tissue growth and long-term gastrointestinal surveillance that clinical development must resolve.

Supporting sources [1] [2] [3] [4]

The population being studied

The development program concerns short bowel syndrome with dependence on parenteral support. It does not test routine IBS or generalized gut-health claims, and anatomy-specific analyses help explain why responses may differ across patients.

Supporting sources [1]

STARS primary result

In 163 randomized and treated patients, weekly support volume fell by a mean 25.5% with apraglutide versus 12.5% with placebo at week twenty-four. More treated patients achieved at least one fewer support day per week at that time.

Supporting sources [1]

Secondary outcomes require nuance

In the colon-in-continuity group at week forty-eight, differences in days off support and enteral autonomy were not statistically significant. A positive primary endpoint therefore does not establish that all clinically desirable outcomes were achieved.

Supporting sources [1]

What remains under evaluation

The trial reported a generally favorable tolerability profile, but the size and duration limit detection of uncommon harms. Long-term consequences of intestinal growth and changing fluid absorption remain relevant to the benefit-risk assessment of GLP-2-directed treatment.

Supporting sources [1] [2]

Why a positive study is not approval

Ironwood’s regulatory update states that FDA requested an additional confirmatory phase 3 study. Its 2026 update describes STARS-2. Apraglutide remains investigational, and the existence of an approved GLP-2 analog does not confer approval on this separate molecule.

Supporting sources [2] [3]